Table 3 Treatment factors according to aspirin and cilostazol treatment groups
|  | Aspirin (n = 34) | Cilostazol (n = 32) | P |
|---|---|---|---|
Admission MBP (mmHg) | 107.6 ± 11.8 | 106.6 ± 15.0 | 0.770 |
3 month MBP (mmHg) | 98.1 ± 11.9 | 95.6 ± 10.2 | 0.370 |
MBP reduction (mmHg) | 9.5 ± 16.9 | 11.3 ± 14.5 | 0.659 |
Antihypertensives | 27 (79.4%) | 22 (68.8%) | 0.322 |
 ARB | 27 (79.4%) | 21 (65.6%) | 0.209 |
 CCB | 11 (32.4%) | 8 (25.0%) | 0.510 |
 BB | 2 (5.9%) | 0 (0.0%) | 0.164 |
Lipid lowering agents | Â | Â | 0.024 |
 Statins | 29 (85.3%) | 32 (100.0%) |  |
 Fibrates | 5 (14.7%) | 0 (0.0%) |  |
Vitamin Supplementation | 4 (11.8%) | 4 (12.5%) | 0.927 |
Oral Hypoglycemic agents | Â | Â | Â |
 Metformin | 8 (23.5%) | 3 (9.4%) | 0.123 |
 Glimepiride | 2 (5.9%) | 3 (9.4%) | 0.592 |
 DPP-4 inhibitors | 3 (8.8%) | 1 (3.1%) | 0.332 |